IT has recently been shown that human dialysable Transfer Factor (TFd) extracted from peripheral blood lymphocytes can be successfully replicated in culture by lymphoblastoid cell lines (Viza et al., 1974 (Viza et al., , 1975 and that such TFd reproduced in vitro can transfer sensitivity to various non-tumour antigens such as candidine, PPD and measles virus (Viza et al., 1975) . However, some of the original data provided by our collaborators, viz. the use of human or culture TFd for transfer in rats, which we have previously reported, has been challenged as unreproducible by our own laboratory (Boucheix and Viza, unpub.) . It was thus desirable to investigate further TFd produced in vitro in order to discover whether a TFd capable of transferring sensitivity towards tumour cells could be replicated in the in vitro cell culture system.
The existence of cell-mediated immunity to transitional-cell carcinoma of the bladder (TCCB) has already been demonstrated (Bubenik et al., 1970; O'Toole et al., 1973; Bloom, Ossorio and Brosman, 1974) . Furthermore, inhibition of leucocyte migration in presence of tumour extracts (Segall et al., 1972) or whole tumour cells (Ax and Tautz, 1974) or formalin-treated tumour cells (Ross et at., 1973) has also been shown. Formalintreated TCCB cells were therefore used in the Leucocyte Migration Test (LMT) to assess patients' immune responses.
Since there is a wide range of cross reactivity in the bladder tumours (Bubenik et al., 1970) , TFd obtained from patients whose leucocyte migration was found to be inhibited in the presence of TCCB cells was used for in vitro replication. The effectiveness of the TFd produced in vitro to transfer TCCB sensitivity to leucocytes from healthy individuals was assessed by the LMT. Preparation of tumour cells.-Surgically removed tumours were minced and a cell suspension was obtained by passage through a metal mesh. Cells were washed 3 times with normal saline and they were subsequently suspended at room temperature in a formalin buffer (Ross et al., 1973) for 12 h. They were afterwards washed 3 times in normal saline and kept at 4°C. Pooled leucocytes (PL) from 5 apparently healthy donors were treated in the same way with the formalin buffer and used in the controls to evaluate the specificity of the migration inhibition by the tumours cells.
Leucocyte Migration Test (LMT).-20 ml of blood were taken in a heparinized (1000 iu) syringe and mixed with 5 ml of plasmagel (Roger Bellon, Paris). The blood was allowed to settle for 60 min and the cells recovered from the enriched leucocyte fraction after 3 washings in TC 199 medium. They were subsequently suspended at 6 x 107 cells/ml and aliquots were mixed at the following ratios of formalin-treated tumour cells to leucocytes-1: 25, 1: 50, 1: 100, 1 : 200. Formalin-treated PL from healthy individuals was used at the same ratios. The suspensions of leucocytes, with or without formalintreated cells, were carefully placed in sterile heparinized capillary tubes (Clay Adams, 75 mm long, 1-1 mm internal diameter) one extremity of which was fire-sealed. The capillaries were subsequently centrifuged for 5 min (150 g) at room temperature and afterwards cut at the interface between the cell pellet and the supernatant. The tubes containing the cell pellets were then placed in sterile migration chambers filled with TC 199 medium containing streptomycin, penicillin and 5% foetal calf serum (FCS) and incubated for 18 h at 37°C. Projection, magnifying x 20 the leucocyte migration area, was used to evaluate the test. The projected area was measured by a planimeter and the mean value of 3 measures was taken. The diameters of migration areas were also measured directly on graph paper. The migration index (MI) is expressed by the following ratio: 40 mean leucocyte migration with TCCB or PL mean leucocyte migration without TCCB and PL
The statistical significance of migration inhibition was calculated using Student's t test. Arn MI less than or equal to 0580 was considered as positive (Table I ). All tests were performed in duplicate or quadruplicate and the mean values taken for the evaluation of the MI.
In vitro test of transfer of the TCCB sensitivity by TFdL.-40 ml of blood was taken from a healthy donor or a patient with TCCB. Leucocytes were separated and suspended in RPMI 1640 medium, supplemented with 10% FCS. An aliquot was incubated with TFdL for 5 h at 37°C in a CO2 humidified atmosphere and gently agitated every hour. TFdL extracted from 107 LC was used for the incubation of 107 lymphocytes. Cells were washed twice at the end of the incubation with TC 199 medium containing 5% FCS and used for the LMT as previously described.
A statistical comparison was made between the MIs of leucocytes in the presence of TCCB cells (Table II) (Lawrence, 1974) . LC not incubated with TFd was also grown, harvested and extracted in the same way. The dialysate thus obtained was used as control and it is designated as Lymphoblastoid Cell Dialysate (LCD).
RESULTS
Leucocytes from 4 healthy donors and 4 patients with TCCB were tested in LMT against formalin-treated TCCB cells before and after incubation with 2 different TFdL preparations. Formalintreated TCCB cells from 7 patients (B.A., T.G., P.G., F.B., T.A., C.R. and P.C.) were used for these tests (Table II) . It should be noted that the cells from P.G. and F.B. were used only in autologous situations, whereas cells from B.A. P.C. and C.R. were used in both autologous and allogeneic tests. All leucocytes were tested with at least 2 TCCB cell preparations before and after TFdL incubation. Two different TFdLs were used: TFdL A12 and TFdL D24.
TFdL A12 was the product of induction of cell line 43912 (Bechet et al., 1972) with TFd from a patient whose leucocytes were found reactive to TCCB cells from the tumour of patient T.A. TFdL D24 was produced by induction of cell line B.F. with TFd from a patient whose lymphocytes were found reactive to tumour cells of patient B.A. and unreactive to T.A. tumour cells.
The results summarized in Table II show that TFdL A12 transferred reactivity in 5/14 cases and TFdL D24 transferred reactivity in 12/15 cases. In the autologous situation, i.e. when the patient's leucocytes were tested with his own tumour cells, transfer was obtained with patients B.A. and P.C. using TFdL D24, and with patients B.A. and P.G. using TFdL A12; the existing reactivity of patient F.B. was increased.
LCD from the uninduced B.F. line used under the same circumstances with the leucocytes of 4 of the TCCB patients who had already shown inhibition when treated with a TFdL preparation, did not increase leucocyte inhibition in the presence of TCCB cells.
Further controls of the specificity of TFdL were performed. It was thus shown that TFdL A12 or D24 did not transfer any reactivity against formalintreated cells obtained from 3 melanoma cell lines (Mel-SKI, IGRI, IGR3) and 3 hypernephromata.
Furthermore when cell line B.F. was induced with TFd obtained from patients with hypernephroma or adenocarcinoma of the colon, whose leucocytes had shown reactivity when tested against autologous or homologous tumour cells, the TFdL thus derived failed to sensitize leucocytes obtained from two healthy volunteers tested against formalin-treated TCCB cells.
DISCUSSION
It has been shown in our laboratory that certain lymphoblastoid cell lines can reproduce TFd extracted from peripheral blood lymphocytes (Viza et al., 1974 (Viza et al., , 1975 . Reactivity to antigens such as PPD, candidine and measles virus can be transferred by this tissue culture TFdL. It is worth noting that although human TFd does not sensitize rats in our hands, as we have already stated in the introduction of this publication, a recent report by some of the co-investigators, whose results claiming a transfer in rats were reported in the very first publication showing TFdL production (Viza et al., 1975) , insists that such a sensitization is possible (Goust, Welch and Fudenberg, 1975 In order to confirm that the dialysate obtained from uninduced LC does not contain any immunological activity, transfer experiments with this dialysate were carried out and they failed to show inhibition in the LMT, whilst the TFdL produced from the same cells was effective.
The absence of inhibition in the LMT, in which hypernephroma or melanoma cells were used as antigens, when a TFdL for TCCB was used for the incubation, suggests the specificity of the TFdL produced in vitro. Similarly, the failure of TFdL induced by TFd from non-TCCB cancer patients to sensitize leucocytes to TCCB cells, also indicates specificity of the TFdL. However, the controversy over the specificity transferred bv TFd is not settled and it must be emphasized that the purpose of the present report is not to conclude this problem, but merely to show that TFdL after a successful induction behaves in a similar fashion to the TFd used for its production. Nevertheless, it must be admitted that the results obtained are in favour of the specificity of TFd. Further work along these lines using specific TFdL for well-defined, non-tumour antigens, is currently in process and should provide a definite answer.
TFdL was found to transfer reactivity against tumour cells not only to leucocytes from healthy individuals but also to the leucocytes of TCCB-unreactive patients. In 3 cases (B.A., P.G. and P.C.), patients' leucocytes unreactive to autologous tumour cells prior to TFdL incubation were found reactive afterwards. In a fourth patient (F.B.) the reactivity was increased after TFdL incubation (Table II) .
Since TFd has already been successfully used for therapy of cancer patients (for recent reviews see Lo Buglio and Neidhart, 1974; Levin et al., 1975; Lawrence, 1974) , it is plausible to suppose that in the near future it will be advantageously replaced by TFdL as the latter proved the transfer of sensitivity to tumour cells in vitro (Pizza et al., 1975) . Indeed, the main restriction of TFd therapy is obtaining large quantities of a TFd with known activity. There are no such limitations for TFdL produced in culture, which can be tested and standardized prior to use.
In the light of the results described here, it seems important for injection of patients to use TFdL capable of sensitizing the patient's leucocytes to the autologous tumour cells now that this can be assessed by the in vitro tests. Preliminary results with 3 patients have already shown that TFdL injection transferred the tumour reactivity in vivo and the patient's leucocytes became reactive to the autologous and allogeneic tumour cells in the LMT 4 days after the second injection, using TFdL from 108 cells per injection. This reactivity persisted for 6 weeks without further injections. In vitro tests performed prior to the TFdL injection had shown that the patient's leucocytes could be rendered reactive to the autologous TCCB cells by the same TFdL used for the subsequent injection of the patient. Further studies aiming for long-term clinical trials with TFdL are now in progress.
